March 7, 2018
Add to Briefcase

ImmunoCellular Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on March 13, 2018

LOS ANGELES, March 7, 2018 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC) today announced that it plans to report fourth quarter and full year 2017 financial results on Tuesday, March 13, 2018. The Company also plans to hold a conference call and webcast on that day at 5:00 pm ET to discuss the 2017 financial results and provide a business update. The call will be hosted by Anthony Gringeri, PhD, President and CEO.  


(877) 853-5636 (toll-free); international dial-in: (631) 291-4544; conference code 4075529.


Interested parties who wish to listen to the webcast should visit the Investor Relations section of ImmunoCellular's website at, under the Events and Presentations tab. A replay of the webcast will be available one hour after the conclusion of the event.

ImmunoCellular Therapeutics Logo. (PRNewsFoto/ImmunoCellular Therapeutics) (PRNewsFoto/IMMUNOCELLULAR THERAPEUTICS)

The conference call will contain forward-looking statements. The information provided on the teleconference is accurate only at the time of the conference call, and ImmunoCellular will take no responsibility for providing updated information except as required by law.

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd., based in Los Angeles, is developing immune-based therapies for the treatment of cancer. ImmunoCellular is focused on advancing its Stem-to-T-Cell research program, which engineers hematopoietic stem cells to generate cytotoxic T cells. Additional assets, for which the Company is seeking partners, include clinical-stage programs - ICT-107, ICT-121 and ICT-140 - which are patient-specific, dendritic cell-based immunotherapies targeting solid tumors. To learn more about ImmunoCellular, please visit


ImmunoCellular Therapeutics, Ltd.
Jane Green
(267) 457-3734 direct
(415) 652-4819 mobile

Lytham Partners, LLC 
Joe Dorame, Robert Blum, or Joseph Diaz
(602) 889-9700


Cision View original content with multimedia:

SOURCE ImmunoCellular Therapeutics, Ltd.

News Provided by Acquire Media